gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · IVVDHealthcareBiotechnology

Invivyd, Inc. Common Stock (IVVD)

$0.6336+8.96%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$0.63▼ 60.66% in range
Nov 3, 2025Low $0.54 · High $2.88Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Invivyd closed at $0.63 on Nov 4, up 8.96%, 78.0% below its 52-week closing high. Volume of 4.5M shares was 0.99× its 20-day average (close to normal).

Split-adjusted performance: -21.4% over one month, -56.6% over six months, -60.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $14.29M, up 21.2% from a year earlier, with a net margin of -310.8%.

Short interest was 37.0M shares at the Oct 15 settlement, up 9.4% from the prior report (15.5% of float, 6.9 days to cover).

Market cap$186.8M294.8M shares
Revenue · quarter$14.3M+21.2% YoY
Diluted EPS$-0.14—
P/E · TTM—P/S 3.2×
Net margin-310.8%Gross 91.1%
Dividend yieldNone
52-week range0.54 – 2.88−78.0% from high
Volume4.5M0.99× 20-day avg
Volatility · 60d107.6%Annualised
Short % of float15.5%6.9 days to cover
Net cash$160.1MCash $160.1M
Next earnings—Not scheduled
Split-adjusted performance
1W +2.8%1M −21.4%3M −3.9%6M −56.6%YTD −74.3%1Y −60.6%3Y −60.9%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum22
Revenue growth62
Net margin51
Value (low P/E)—
Size44

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short37.0M+9.4% vs prior
Days to cover6.9Settled Oct 15
% of float15.5%
Short vol. 10d56.5%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
IVVDInvivyd$0.6336+8.96%−56.6%+21.2%−310.8%—$186.8M
ACOGAlpha Cognition$8.53+4.02%+33.7%+267.6%−144.3%—$185.8MCompare
ARTVArtiva Biotherapeutics$4.22+0.48%−65.9%———$206.3MCompare
STROSutro Biopharma$9.94+4.52%−73.6%−84.6%−391.6%—$164.8MCompare
PLXProtalix BioTherapeutics$2.69+3.07%+33.2%+27.1%19.0%11.4$216.7MCompare
PALIPalisade Bio$1.25+1.63%−37.5%—−2114.8%—$217.8MCompare
IKTInhibikase Therapeutics$1.57+5.74%−22.1%———$218.4MCompare
DTILPrecision BioSciences$8.12+16.50%+8.0%−100.0%——$224.1MCompare
PROKProKidney$1.12+4.67%−42.9%−32.1%−18948.0%—$234.1MCompare

News about Invivyd

All news →

No recent articles focused on Invivyd.

Quick answers

What does Invivyd do?
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S.
What is IVVD's market cap?
$186.76M, based on the Nov 4 close of $0.63.
Does Invivyd pay a dividend?
No regular cash dividend has been paid in the last year.
How much of IVVD is sold short?
37.0M shares, 15.5% of float, as of Oct 15, 2026.
What sector is IVVD in?
Healthcare, in the Biotechnology industry.

About Invivyd

Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.

HQ: New Haven, CT122 employeesListed Aug 6, 2021invivyd.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology